EICHOR
● Active Not Recruiting
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Condition: Cervical Cancer · Advanced Cancer · Sponsor: Grupo Español de Investigación en Cáncer de Ovario
About this study
Patients with locally advanced cervical cancer (LACC) despite definitive chemo-radiotherapy, has a poor progression-free survival (PFS) and overall survival (OS). The hypothesis is that the use of TSR-042, checkpoint inhibitor, as consolidation therapy following concurrent chemo-radiation would increase PFS in these patients. The incorporation of immunotherapy after chemo-radiation is one the best scenarios for this approach, since takes advantages of "the ideal microenvironment" created after radiation. In a similar rationale, the phase 3 study that compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy, showed that progression-free survival was significantly longer with durvalumab than with placebo in all sub-groups regardless of response obtained to chemotherapy, namely patients with stable disease (SD) gained the same benefit that patients with partial response (PR). Due to the aforementioned biology of cervical cancer, the proven activity of anti programmed cell death protein 1 (Anti-PD1) agents in metastatic and/or recurrent cervical cancer and the poor PFS and OS in patients with LACC despite definitive chemo-radiotherapy, we consider to analyze the Anti-PD1 agent, TSR-042 as maintenance therapy after concurrent chemo-radiation (CCRT)
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (29)
| Hospital General Universitario de Elche | Elche, Alicante, Spain | — |
| Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea | Donostia / San Sebastian, Gipuzkoa, Spain | — |
| ICO Girona | Girona, Girona, Spain | — |
| Hospital Universitario La Paz | Madrid, Madrid, Spain | — |
| Hospital Universitario 12 de Octubre | Madrid, Madrid, Spain | — |
| Hospital Álvaro Cunqueiro | Vigo, Pontevedra, Spain | — |
| Hospital Universitario Virgen del Rocío | Seville, Sevilla, Spain | — |
| Instituto Valenciano de Oncología | Valencia, Valencia, Spain | — |
| Hospital Clínico Universitario de Valencia | Valencia, Valencia, Spain | — |
| Hospital La Fe | Valencia, Valencia, Spain | — |
| H Vall d'Hebron | Barcelona, Spain | — |
| Hospital Clínic | Barcelona, Spain | — |
+ 17 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03833479